Cure8 research brief
Co-occurring immune-mediated diseases (including IBD and psoriasis) are reported repeatedly with MS in research. Understanding these relationships could affect monitoring, diagnosis timing, and research into shared causes.
Clinicians who treat MS and immune-mediated diseases, researchers studying shared autoimmune mechanisms, and adult patients living with MS or IBD interested in comorbidity patterns.
The review found recurrent evidence that autoimmune thyroid disease, type 1 diabetes, psoriasis, inflammatory bowel disease (IBD), and bullous pemphigoid co-occur with MS more often than expected in some studies. Other conditions such as rheumatoid arthritis, lupus, vitiligo, and atopic disorders showed more mixed findings.
Some studies reported higher rates of certain conditions (for example, psoriasis and IBD) diagnosed after MS, and others found that previously diagnosed immune diseases were associated with later MS, but estimates varied and were often inconsistent.
There is limited and heterogeneous evidence about whether these comorbid immune diseases affect MS activity, disability, or progression; a few studies suggested worse disability or MRI outcomes with type 1 diabetes, but for most conditions the data were inconclusive.
The authors conclude that current evidence cannot establish a clear MS prodrome or distinct MS subgroups defined by co-occurring immune diseases and call for longitudinal studies with standardized definitions, clear timing of diagnoses, treatment data, and confounder adjustment.
This record is a scoping review (abstract-level summary from Frontiers in Immunology). It summarizes published observational studies up to Feb 28, 2026 and highlights heterogeneity across study designs, populations, and definitions. It does not provide new clinical trial results or establish causal relationships.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Candidalysin is a toxin from Candida albicans that can damage epithelial barriers and trigger inflammation. If candidalysin contributes to intestinal inflammation or barrier dysfunction, it could help explain fungal...
This review links molecular pathways (acetylation and ubiquitination) to key inflammatory cell-death mechanisms relevant to ulcerative colitis; confirming these links in intestinal cells could identify new biomarkers or...
This study highlights that people who go on to develop myasthenia gravis had higher rates of other autoimmune diagnoses in the years beforehand, which may be relevant for clinicians tracking autoimmune comorbidity...
